This study is being done to test the safety and efficacy of the study drug LY3852710 for the treatment of diabetic peripheral neuropathic pain.
1 Primary · 6 Secondary · Reporting Duration: Baseline, Up to Week 8
125 Total Participants · 2 Treatment Groups
Primary Treatment: LY3852710 · Has Placebo Group · Phase 2
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|Did not meet criteria||50.0%|
|Artemis Institute for Clinical Research||100.0%|